BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
Glass House Brands Announces Accelerated 2026 Expansion Strategy
Safe Supply Announces Sale of NIRLAB Drug Analysis Device to Far North Resources Inc., Advancing Indigenous-Led Community Safety and Rapid Drug Identification
Light AI Appoints John R. Luna as Chief Executive Officer
Therma Bright Sells an Additional 200-Units of Venowave(TM) to Strategic Distribution Partner Gen-X Med
Rocket Doctor AI increases private placement to $5.2M
Telo Genomics arranges $1.2-million debenture financing
ROCKET DOCTOR AI INC. ANNOUNCES UPSIZE ON LISTED ISSUER FINANCING EXEMPTION (LIFE) NON-BROKERED PRIVATE PLACEMENT
Entheon Announces Execution of Business Combination Agreement with Nutravisor
Bionxt discusses cladribine ODF study
Ventripoint Announces Closing of Non-Brokered Units Private Placement
Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF
Rocket Doctor AI increases private placement to $4.5M